Date: 2013-08-28
Type of information: Licensing agreement
Compound: Novexatin®
Company: Novabiotics (UK) Taro Pharmaceutical (USA)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism: Novexatin® is a topical treatment for fungal nail infections (onychomycosis). The active pharmaceutical agent of this medicinal candidate is NovaBiotics’ novel, patented antifungal peptide, NP213, which was developed specifically as a safe, fast-acting nail penetrating fungicidal molecule from the Company’s proprietary antimicrobial peptide platform.
Disease: fungal nail infections (onychomycosis)
Details: * On August 28, 2013, NovaBiotics has announced that it has entered into an exclusive agreement with Taro Pharmaceuticals North America, Inc. (“Taro”) to licence and co-develop Novexatin®, the Company’s first-in-class antifungal peptide treatment for fungal nail infections. Novexatin® is an investigational drug that is expected to enter a multi-centre Phase IIb study for mild-to-moderate onychomycosis in the US. NovaBiotics and Taro will jointly manage the study and other development activities for Novexatin®, with Taro as lead partner in the programme.
In addition to Novexatin®, the Company is developing Lynovex®, for cystic fibrosis (CF) an antibacterial compound that also breaks down excess mucous produced in the airways of CF patients that is expected to enter a Phase IIa study in Q1 2014; Novamycin®, a peptide antifungal agent against Candida and Aspergillus; Novarifyn®, a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections, including MRSA.
Financial terms:
Latest news:
